FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
FDA General

Chief Scientist Tapped as Woodcock Replacement

FDA commissioner Robert Califf names agency chief scientist Namandj Bumpus as the replacement for retiring principal deputy commissioner Janet Woodcoc...

latest-news-card-1
Human Drugs

More Novo Nordisk Semaglutide Legal Actions

Novo Nordisk says it is seeking legal action against two compounding pharmacies it says are selling adulterated and misbranded drugs claiming to conta...

latest-news-card-1
Human Drugs

AbbVie Seeks Accelerated OK for Lung Cancer Drug

Based on new clinical study data, AbbVie says it will seek accelerated approval for telisotuzumab-vedotin in patients with c-Met protein overexpressio...

latest-news-card-1
Federal Register

Info Collection on Combination Product Jurisdiction

Federal Register notice: FDA sends to OMB an information collection extension entitled Product Jurisdiction and Combination Products 21 CFR Parts 3 a...

latest-news-card-1
Human Drugs

UCB on Pregnancy Safety Studies

UCB makes suggestions for FDA to consider in developing a framework to optimize post-approval pregnancy safety studies.

latest-news-card-1
Medical Devices

FDA Clears GE Critical Care Suite 2.1

FDA clears GE Healthcares Critical Care Suite 2.1 that includes a pneumothorax algorithm.

latest-news-card-1
Human Drugs

Arcturus Therapeutics Orphan Status for ARCT-032

FDA grants Arcturus Therapeutics an orphan drug designation for ARCT-032 and its use to treat cystic fibrosis.

latest-news-card-1
Federal Register

Regulatory Review Determinations on 8 NDAs

Federal Register notices: FDA publishes notices about the regulatory review period determinations for eight drug products sponsored by KemPharm, Apell...

latest-news-card-1
Human Drugs

Karuna NDA for Schizophrenia Accepted by FDA

FDA accepts for review a Karuna Therapeutics NDA for KarXT (xanomeline-trospium) for treating schizophrenia in adults.

latest-news-card-1

Praise for Graft-Versus-Host Drug Guidance

Stakeholders comment positively on an FDA draft guidance on developing products to prevent or treat graft-versus-host disease.